{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-270370","form_type":"8-K","ticker":"BMRN","cik":"0001048477","company_name":"BIOMARIN PHARMACEUTICAL INC","filed_at":"2023-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.026494+00:00","generated_at":"2026-06-08T21:52:45.010224+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"BioMarin CEO Jean-Jacques Bienaimé retiring; Alexander Hardy appointed new CEO","bullets":["Jean-Jacques Bienaimé retires as President, CEO and Chairman on Nov 30, 2023; remains on board until 2024 annual meeting.","Alexander Hardy (ex-Genentech CEO) becomes President and CEO and joins board effective Dec 1, 2023.","Hardy receives $1,050,000 annual base salary, $900,000 signing bonus, and ~$15.5M in equity grants with multi-year vesting.","Bienaimé eligible for 2023 bonus at 120% of base salary if he remains director/consultant; consulting pays $146k/mo then $73k/mo.","Lead independent director Richard A. Meier becomes Board Chair effective Dec 1, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-270370","json":"https://secwatch.observer/filing/0001193125-23-270370.json","markdown":"https://secwatch.observer/filing/0001193125-23-270370.md","text":"https://secwatch.observer/filing/0001193125-23-270370.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1048477/000119312523270370/0001193125-23-270370-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1048477/000119312523270370/d578678d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T21:52:45.010224+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"26f09fb2d1","claim":"Richard A. Meier was appointed as Chair of the Board at BIOMARIN PHARMACEUTICAL INC.","evidence_excerpt":"Richard A. Meier, BioMarin’s lead independent director, will assume the role of Chair of the Board, effective December 1, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1048477/000119312523270370/0001193125-23-270370-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chair of the Board"}],"fact_type":"executive_change"},{"claim_id":"8f40a40d70","claim":"Jean-Jacques Bienaimé retired as President, Chairman and Chief Executive Officer at BIOMARIN PHARMACEUTICAL INC.","evidence_excerpt":"Jean-Jacques Bienaimé will retire as the Company’s President, Chairman and Chief Executive Officer effective as of close of business on November 30, 2023","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1048477/000119312523270370/0001193125-23-270370-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"retired"},{"label":"Role","value":"President, Chairman and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"e05845e0be","claim":"Alexander Hardy was appointed as President and Chief Executive Officer at BIOMARIN PHARMACEUTICAL INC.","evidence_excerpt":"the Company announced the appointment of Alexander Hardy, age 55, to serve as the Company’s President and Chief Executive Officer and as a member of the Board, effective as of December 1, 2023","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1048477/000119312523270370/0001193125-23-270370-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}